While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected rangeConsented subjects now ...

First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) ...

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Primary endpoint more than doubled versus standard induction chemotherapy ...

Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL)—the most common ...

ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.

About one-third of families with a child undergoing treatment for acute lymphoblastic leukemia experienced catastrophic income loss during therapy, with many developing new material hardships over the ...